Market Place
Sourcing Support
Lassen reels in $85M Series B for PhII testing in thyroid eye disease
19 Dec 2023 //
ENDPTS
Lassen Announces Closing of Oversubscribed $85 Million Series B Financing
19 Dec 2023 //
BUSINESSWIRE
Lassen Therapeutics Presents Preclinical Data on LASN01
02 Oct 2023 //
BUSINESSWIRE
Lassen Presents Data on LASN01 for Treatment of Idiopathic Pulmonary Fibrosis
11 Sep 2023 //
BUSINESSWIRE
Lassen Presents Phase I Data on LASN01, an IL-11 Receptor-Blocking Antibody
24 May 2023 //
BUSINESSWIRE
Lassen Presents New Preclinical Data on IL-11 Receptor-blocking
15 Jun 2022 //
BUSINESSWIRE
Lassen Tx Presents Data Demonstrating Preclinical Anti-fibrotic Effect of LASN01
17 May 2022 //
BUSINESSWIRE
Lassen Tx Announces Presentations on Novel IL-11 Receptor-Blocking Ab
03 May 2022 //
BUSINESSWIRE
Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer
18 Nov 2021 //
BUSINESSWIRE
Lassen Therapeutics to Present at the 5th Annual IPF Summit
26 Aug 2021 //
BUSINESSWIRE
Lassen Therapeutics, Cedars Sinai team up on lung fibrosis work
25 Mar 2021 //
FIERCEBIOTECH
Lassen Announces Collaboration with Cedars Sinai Medical Center to Study
24 Mar 2021 //
BUSINESSWIRE
Lassen Announces Collaboration with the Olivia Newton-John Cancer Research
09 Feb 2021 //
BUSINESSWIRE
Lassen Announces Collaboration with the Olivia Newton-John Cancer Research
09 Feb 2021 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.